AAV-hTERT / Libella Gene Therap - LARVOL DELTA

Telomere Protection Attenuates the Development of Hypertrophic Cardiomyopathy (ASGCT 2026) - "Methods We developed a cardiomyocyte-specific gene therapy, AAV9-hTERT (JV101)...Conclusion Collectively, our results indicate that JV101 therapy effectively inhibits the progression of HCM. The observed efficacy of prophylactic JV101 administration is likely attributed to the modulation of the telomere-p53-mitochondrial axis, highlighting its considerable potential as a novel preventive strategy for HCM."

Cardiomyopathy • Cardiovascular • Fibrosis • Gene Therapies • Hypertrophic Cardiomyopathy • Immunology